Search. Learn. Save

Platform for Pharmaceutical Products for Healthcare Professionals
Search By
☰ Generic Formulas

Generic Formulas X

Imipramine

Imipramine: A Comprehensive Guide to an Essential Tricyclic Antidepressant

Introduction

Imipramine, a tricyclic antidepressant (TCA), has played a pivotal role in the treatment of depression and related psychiatric disorders since its introduction in the 1950s. It was the first TCA to be marketed and has since become a benchmark for other antidepressants. Its efficacy, broad therapeutic applications, and well-studied pharmacological profile make it a cornerstone in the history of psychopharmacology.

Historical Background

Imipramine was synthesized in the 1950s by Swiss pharmaceutical company Geigy (now part of Novartis). Initially developed as an antipsychotic, its antidepressant properties were quickly discovered during clinical trials. Its success opened the door for the development of a new class of medications: tricyclic antidepressants.

Chemical Structure and Classification

Imipramine belongs to the tricyclic antidepressant family, named for their three-ring chemical structure. Its chemical name is 5-[3-(dimethylamino)propyl]-10,11-dihydro-5H-dibenz[b,f]azepine. The structure of imipramine closely resembles other TCAs like amitriptyline and nortriptyline.

Mechanism of Action

Imipramine works primarily by inhibiting the reuptake of the neurotransmitters serotonin and norepinephrine in the brain. This increases the concentration of these neurotransmitters in the synaptic cleft, enhancing neurotransmission and improving mood and emotional state. It also blocks other receptors including histaminic, cholinergic, and alpha-adrenergic receptors, which contributes to its side effects.

Key Receptor Interactions:

  • Serotonin Transporter (SERT): Inhibition leads to increased serotonin levels.

  • Norepinephrine Transporter (NET): Inhibition leads to increased norepinephrine levels.

  • Histamine H1 Receptors: Blockade causes sedation and weight gain.

  • Muscarinic Receptors: Blockade leads to anticholinergic effects.

  • Alpha-1 Adrenergic Receptors: Blockade can cause orthostatic hypotension.

Therapeutic Uses

1. Major Depressive Disorder (MDD)

Imipramine is primarily used to treat moderate to severe depression. It is particularly effective in patients who do not respond to selective serotonin reuptake inhibitors (SSRIs). It improves mood, energy, and appetite and reduces suicidal ideation.

2. Nocturnal Enuresis (Bedwetting) in Children

One of the earliest off-label uses of imipramine was for the treatment of childhood enuresis. Its anticholinergic properties reduce bladder contractility, and its effect on REM sleep alters the sleep cycle, potentially reducing bedwetting episodes.

3. Panic Disorder and Anxiety

Imipramine is effective in the treatment of panic disorder, with or without agoraphobia. It reduces the frequency and severity of panic attacks.

4. Chronic Pain Syndromes

TCAs like imipramine are used off-label for neuropathic pain, fibromyalgia, and migraine prophylaxis. They alter pain perception at the central nervous system level.

5. Obsessive-Compulsive Disorder (OCD)

Although clomipramine is the TCA of choice for OCD, imipramine has shown some effectiveness, especially in combination therapy.

6. Attention-Deficit Hyperactivity Disorder (ADHD)

In certain cases, imipramine has been used to treat ADHD, particularly when stimulants are contraindicated.

Dosage and Administration

Imipramine is available in oral tablet form and as an injectable for hospital use.

Adult Dosing (Depression):

  • Initial dose: 75 mg/day in divided doses

  • Maintenance dose: 75–150 mg/day (can be increased up to 300 mg/day in hospitalized patients)

  • Maximum dose: 300 mg/day

Pediatric Dosing (Enuresis):

  • 6–8 years: 25 mg at bedtime

  • 9–12 years: 25–50 mg at bedtime

  • 12+ years: 50–75 mg at bedtime

Dose adjustments must be made cautiously, especially in the elderly and those with hepatic or renal impairment.

Pharmacokinetics

  • Absorption: Well absorbed from the gastrointestinal tract.

  • Bioavailability: Variable due to first-pass metabolism.

  • Half-life: 11–25 hours

  • Metabolism: Hepatic, mainly via CYP2D6 to desipramine (active metabolite).

  • Excretion: Renal

Side Effects

Imipramine’s wide receptor activity contributes to a diverse side effect profile:

Common Side Effects:

  • Dry mouth

  • Constipation

  • Blurred vision

  • Drowsiness

  • Weight gain

  • Dizziness

Serious Side Effects:

  • Cardiotoxicity (especially in overdose)

  • Seizures

  • Serotonin syndrome (if combined with serotonergic drugs)

  • Orthostatic hypotension

  • Urinary retention

Anticholinergic Effects:

These are particularly troublesome in the elderly and may lead to confusion, delirium, or falls.

Contraindications

  • Recent myocardial infarction

  • Cardiac conduction abnormalities

  • Concurrent use with MAO inhibitors (risk of serotonin syndrome)

  • Severe liver disease

  • Hypersensitivity to imipramine or other TCAs

Drug Interactions

Imipramine interacts with a wide range of medications:

  • MAO Inhibitors: Risk of hypertensive crisis or serotonin syndrome.

  • SSRIs/SNRIs: Increased risk of serotonin syndrome.

  • Anticholinergic drugs: Additive side effects.

  • CYP2D6 inhibitors: Can increase plasma levels of imipramine.

  • Alcohol and CNS depressants: Enhanced sedative effects.

Monitoring and Safety

Monitoring Parameters:

  • ECG (baseline and periodically, especially in older adults)

  • Liver function tests

  • Blood pressure

  • Mental status and suicidal ideation

  • Plasma levels in some treatment-resistant cases

Overdose Risks:

TCAs are among the most lethal drugs in overdose due to their cardiac toxicity. Signs include arrhythmias, seizures, and CNS depression. Activated charcoal and supportive measures are used in overdose situations.

Use in Special Populations

Pregnancy:

Imipramine is classified as Category D (positive evidence of human fetal risk), but benefits may outweigh risks in severe depression.

Lactation:

It is excreted in breast milk; caution is advised.

Elderly:

More susceptible to side effects like confusion and orthostatic hypotension. Lower doses are recommended.

Comparisons with Other Antidepressants

Feature Imipramine SSRIs (e.g., fluoxetine) SNRIs (e.g., venlafaxine)
Onset of Action 2–4 weeks 2–4 weeks 1–2 weeks
Sedation Common Less common Moderate
Anticholinergic High Minimal Minimal
Cardiovascular Risk High Low Low
Overdose Risk High Moderate Moderate

While SSRIs are generally better tolerated, imipramine remains a valuable option, particularly for patients unresponsive to newer agents.

Withdrawal and Discontinuation

Discontinuing imipramine abruptly can lead to withdrawal symptoms:

  • Nausea

  • Headache

  • Irritability

  • Sleep disturbances

  • Flu-like symptoms

Tapering the dose gradually under medical supervision is crucial to minimize withdrawal effects.

Patient Education Tips

  • Take the medication exactly as prescribed.

  • Do not abruptly stop taking it.

  • Report any signs of suicidal thoughts or mood worsening.

  • Avoid alcohol and CNS depressants.

  • Rise slowly from sitting or lying positions to avoid dizziness.

Current Research and Future Directions

Though older, imipramine continues to be studied for its potential roles in treatment-resistant depression and chronic pain. Its metabolite, desipramine, is also under investigation for neurodegenerative conditions such as Parkinson’s disease.

Conclusion

Imipramine remains a robust and time-tested antidepressant, especially useful in cases where modern agents may fall short. Despite its side effects and overdose risks, it offers powerful therapeutic benefits for depression, anxiety, enuresis, and more. With proper monitoring and patient education, it continues to hold a relevant place in psychiatric and primary care practice.